文献速递泌尿生殖与妇科肿瘤放疗放疗物理与技术

高危前列腺癌仅前列腺与全盆腔放疗的晚期毒性和生活质量:POP-RT随机试验

Late toxicity and quality of life with prostate only or whole pelvic radiation therapy in high risk prostate cancer (POP-RT): A randomised trial.
PubMed 文献 · Radiother Oncol · 2020-01-07

POP-RT随机试验比较高危、淋巴结阴性前列腺癌仅前列腺放疗(PORT,68 Gy/25次)与全盆腔放疗(WPRT,前列腺68 Gy/25次+盆腔50 Gy/25次)的毒性和生活质量。共224例患者随机分组,中位随访44.5个月,WPRT组≥2级晚期泌尿毒性高于PORT组(17.7% vs 7.5%,p=0.03),但两组生活质量各领域评分无差异。

要点

  • WPRT组≥2级晚期泌尿毒性显著高于PORT组(17.7% vs 7.5%,p=0.03)。
  • 两组≥2级晚期胃肠道毒性相似(6.5% vs 3.8%,p=0.39),未见4级毒性。
  • 尽管泌尿毒性增加,两组患者报告的生活质量各领域评分无差异。

核心结论

  • 与仅前列腺放疗相比,全盆腔放疗增加≥2级晚期泌尿毒性,但未反映在患者报告的生活质量上。

研究设计与样本

  • 随机试验纳入224例高危、淋巴结阴性前列腺癌患者,PORT组114例,WPRT组110例,2011年11月至2017年8月入组,中位随访44.5个月。
  • 分层因素包括TURP、Gleason评分、基线PSA和雄激素剥夺治疗(ADT)类型,强制使用图像引导调强放疗(IG-IMRT)和2年ADT。

主要发现

  • WPRT组与PORT组≥2级晚期胃肠道毒性相似(6.5% vs 3.8%,p=0.39)。
  • WPRT组≥2级晚期泌尿毒性高于PORT组(17.7% vs 7.5%,p=0.03)。
  • 剂量学分析显示WPRT组膀胱接受30-40 Gy体积更高(V30:60% vs 36%,p<0.001;V40:41% vs 25%,p<0.001)。
  • 两组生活质量各领域评分无差异,未观察到RTOG 4级毒性。

关键数值与推荐

  • PORT组前列腺处方剂量68 Gy/25次,WPRT组前列腺68 Gy/25次、盆腔50 Gy/25次。
  • 入组条件为局限性前列腺腺癌且淋巴结受累风险>20%。

临床怎么用

  • 高危、淋巴结阴性前列腺癌选择全盆腔放疗时,应关注晚期泌尿毒性增加的风险,尽管生活质量未见差异。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

AIM: To report toxicity and quality of life (QOL) outcomes from a randomised trial of prostate only versus whole pelvic radiotherapy in high risk, node negative prostate cancer. MATERIALS/METHODS: Patients with localised prostate adenocarcinoma and nodal involvement risk > 20%, were randomised to prostate only (PORT, 68 Gy/25# to prostate) and whole pelvis (WPRT, 68 Gy/25# to prostate and 50 Gy/25# to pelvis) arms with stratification for TURP, Gleason score, baseline PSA, and type of androgen deprivation therapy (ADT). Image guided intensity modulated radiotherapy (IG-IMRT) and two years of ADT were mandatory. Acute and late genitourinary (GU) and gastrointestinal (GI) toxicities were graded using RTOG grading. QOL was assessed using EORTC QLQ-C30 and PR-25 questionnaire pre-treatment and every 3-6 months post RT. RESULTS: Total 224 patients were randomised (PORT 114, WPRT 110) from November 2011 to August 2017. Median follow up was 44.5 months. No RTOG grade IV toxicity was observed. Acute GI and GU toxicities were similar between both the arms. Cumulative ≥ grade II late GI toxicity was similar for WPRT and PORT (6.5% vs. 3.8%, p = 0.39) but GU toxicity was higher (17.7% vs. 7.5%, p = 0.03). Dosimetric analysis showed higher bladder volume receiving 30-40 Gy in the WPRT arm (V30, 60% vs. 36%, p < 0.001; V40, 41% vs. 25%, p < 0.001). There was no difference in QOL scores of any domain between both arms. CONCLUSION: Pelvic irradiation using hypofractionated IG-IMRT resulted in increased grade II or higher late genitourinary toxicity as compared to prostate only RT, but the difference was not reflected in patient reported QOL. CLINICALTRIALS.GOV NCT02302105: Prostate Only or Whole Pelvic Radiation Therapy in High Risk Prostate Cancer (POP-RT).

来源:Radiother Oncol,查看原文。版权归原作者所有。

引用

  1. Murthy V, Maitre P, Bhatia J, et al. Late toxicity and quality of life with prostate only or whole pelvic radiation therapy in high risk prostate cancer (POP-RT): A randomised trial. Radiother Oncol. 2020. PMID: 31923712. doi:10.1016/j.radonc.2019.12.006

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。